Physician profile
Shaun Roe
NPI 1750558797
$5,006.89
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $685 · 2020: $798 · 2021: $1,119 · 2022: $1,056 · 2023: $1,257 · 2024: $91.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,320 · Education: $29.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,320.08 |
| Education | $29.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $823.09 | 2019-2023 | Wegovy |
| Abbvie INC. | $741.87 | 2021-2023 | Vraylar, Ubrelvy, Qulipta |
| Merck Sharp & Dohme LLC | $546.47 | 2019-2023 | Belsomra, Steglatro, Segluromet |
| Astrazeneca Pharmaceuticals Lp | $487.82 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $459.25 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $401.87 | 2019-2024 | Jardiance, Synjardy |
| Amgen INC. | $305.41 | 2019-2023 | Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $170.64 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $157.17 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $131.61 | 2019-2023 | Ajovy |
| Pfizer INC. | $112.92 | 2019-2024 | |
| Glaxosmithkline, LLC. | $85.38 | 2022-2023 | Arexvy, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $76.19 | 2021-2023 | Camzyos, Eliquis |
| Upsher-Smith Laboratories LLC | $64.36 | 2020-2021 | |
| Allergan, INC. | $58.92 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.26 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $45.01 | 2022-2023 | Quviviq |
| Abbott Laboratories | $42.13 | 2022-2024 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $39.53 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.20 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $28.91 | 2019-2020 | |
| Shire North American Group INC | $28.42 | 2019 | |
| Organon LLC | $24.65 | 2021-2023 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $16.36 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.36 | 2021 | |
| Eisai INC. | $14.72 | 2021 | |
| Sanofi Pasteur INC. | $13.68 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.98 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.50 | 2020 | |
| Mylan Specialty L.P. | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaun Roe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.